nach oben

Erschienen in:

08.06.2016 | Original Article

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway

verfasst von: Jean-Nicolas Cornu, Etienne Audet-Walsh, Sarah Drouin, Pierre Bigot, Antoine Valeri, Georges Fournier, Abdel-Rahmène Azzouzi, Morgan Roupret, Luc Cormier, Stephen Chanock, Chantal Guillemette, Olivier Cussenot, Eric Lévesque, Géraldine Cancel-Tassin

Erschienen in: World Journal of Urology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

A few preliminary studies have suggested a link between some genetics variants and benign prostatic hyperplasia (BPH). Our goal was to study the link between a set of single nucleotide polymorphisms (SNPs) implicated in the steroid pathway and accurate measurement of prostate volume in a cohort of men who underwent radical prostatectomy.

Methods

Clinical and pathological data including prostate weight were obtained from 611 Caucasian patients with small volume, localized prostate cancer treated by radical prostatectomy. Patients were genotyped for 90 SNPs located inside or nearby genes implicated in the steroid pathway (Sequenom iPLEX). Correlation between prostate weight and genotypes from each SNP was studied by analysis of covariance, adjusted on age and tumor stage. A Bonferroni correction was applied, and the SNPs implicated were then incorporated in a multivariable model.

Results and limitations

Seven SNPs located in or nearby genes implicated in steroid hormone metabolism were significantly associated with prostate volume: HSD17B2 (rs1119933), ESR2 (rs8006145), SULT2B1 (rs279451), NQO1 (rs2917670), ESR1 (rs1569788), GSTP1 (rs1138272), and CYP19A1 (rs17523880). Significant association was maintained after multivariate analysis for four SNPs, indicating their independent association with prostate volume. The power of the association of each SNP with prostate volume was comparable to the effect of age. The strongest associations were found with variants in ESR1, ESR2, HSD17B2, and CYP19A1 genes, indicating a potential role of the estrogen signaling pathway in genesis of BPH.

Conclusions

Our results are in favor of an implication of estrogen biotransformation and signaling pathways in the pathophysiology of BPH.

Nur mit Berechtigung zugänglich

Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 95(1):87–100CrossRefPubMed

Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474–479PubMed

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140CrossRefPubMed

Lepor H (2005) Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 7(Suppl 7):S3–S11

Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–203CrossRefPubMed

DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, Kastner C, Kirby M (2015) Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. BJU Int 117(5):801–808CrossRefPubMed

He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 19(1):7–13CrossRefPubMed

Freeman MR, Solomon KR (2011) Cholesterol and benign prostate disease. Differentiation 82(4–5):244–252CrossRefPubMedPubMedCentral

McLaren ID, Jerde TJ, Bushman W (2011) Role of interleukins, IGF and stem cells in BPH. Differentiation 82(4–5):237–243CrossRefPubMed

10.

Ricke WA, Macoska JA, Cunha GR (2011) Developmental, cellular and molecular biology of benign prostatic hyperplasia. Differentiation 82(4–5):165–167CrossRefPubMedPubMedCentral

11.

Macoska JA (2011) Chemokines and BPH/LUTS. Differentiation 82(4–5):253–260CrossRefPubMedPubMedCentral

12.

Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199CrossRefPubMedPubMedCentral

13.

Meikle AW, Bansal A, Murray DK, Stephenson RA, Middleton RG (1999) Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. Urology 53(4):701–706CrossRefPubMed

14.

Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC (1997) Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 157(3):876–879CrossRefPubMed

15.

Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC, Thiagamoorthy G, Ambrose C, Gonzalez-Maffe J, Bennett PR, Palmer T, Walley A, Järvelin MR, Khullar V, Chapple C (2014) Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol 66(4):752–768CrossRefPubMedPubMedCentral

16.

Yeager M, Orr N, Hayes RB et al (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645–649CrossRefPubMed

17.

Audet-Walsh E et al (2012) The impact of germline genetic variations in hydroxysteroid (17-Beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Eur Urol 62:88–96CrossRefPubMed

18.

Gudmundsson J, Besenbacher S, Sulem P (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2:62ra92CrossRefPubMedPubMedCentral

19.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ (2013) Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. J Urol 189:845–848CrossRefPubMed

20.

Giri A, Edwards TL, Motley SS, Byerly SH, Fowke JH (2015) Genetic determinants of metabolism and benign prostate enlargement: associations with prostate volume. PLoS ONE 10(7):e0132028CrossRefPubMedPubMedCentral

21.

Keene KL, Mychaleckyj JC, Smith SG, Leak TS, Perlegas PS, Langefeld CD, Herrington DM, Freedman BI, Rich SS, Bowden DW, Sale MM (2008) Comprehensive evaluation of the estrogen receptor alpha gene reveals further evidence for association with type 2 diabetes enriched for nephropathy in an African American population. Hum Genet 123(4):333–341CrossRefPubMedPubMedCentral

22.

Ho CK, Nanda J, Chapman KE, Habib FK (2008) Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 197(3):483–491CrossRefPubMed

23.

Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, Koji T (2003) Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 88(3):1333–1340CrossRefPubMed

24.

Royuela M, de Miguel MP, Bethencourt FR, Sánchez-Chapado M, Fraile B, Arenas MI, Paniagua R (2001) Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 168(3):447–454CrossRefPubMed

25.

Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, Sinisi AA (2001) Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86(5):2051–2055PubMed

26.

Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98(11):6330–6335CrossRefPubMedPubMedCentral

27.

Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95(26):15677–15682CrossRefPubMedPubMedCentral

28.

Kim SK, Chung JH, Park HC, Kim JH, Ann JH, Park HK, Lee SH, Yoo KH, Lee BC, Kim YO (2015) Association between polymorphisms of estrogen receptor 2 and benign prostatic hyperplasia. Exp Ther Med 10(5):1990–1994PubMedPubMedCentral

29.

Ho CK, Habib FK (2011) Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 8(1):29–41CrossRefPubMed

30.

Kumar V, Banerjee BD, Datta SK, Yadav CS, Singh S, Ahmed RS, Gupta S (2014) Association of CYP1A1, CYP1B1 and CYP17 gene polymorphisms and organochlorine pesticides with benign prostatic hyperplasia. Chemosphere 108:40–45CrossRefPubMed

31.

Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25(24):3596–3602CrossRefPubMed

32.

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML (2014) CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples. Pharmgenomics Pers Med 14(7):163–171

33.

McPherson SJ et al (2001) Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142:2458–2467PubMed

34.

Jarred RA (2002) Prostate phenotypes in estrogen-modulated transgenic mice. Trends Endocrinol Metab 13:163–168CrossRefPubMed

35.

Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C (2014) Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. Clin Cancer Res 20(11):2971–2983CrossRefPubMed

Titel: Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway
verfasst von: Jean-Nicolas Cornu
Etienne Audet-Walsh
Sarah Drouin
Pierre Bigot
Antoine Valeri
Georges Fournier
Abdel-Rahmène Azzouzi
Morgan Roupret
Luc Cormier
Stephen Chanock
Chantal Guillemette
Olivier Cussenot
Eric Lévesque
Géraldine Cancel-Tassin
Publikationsdatum: 08.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 2/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1869-4

Neu im Fachgebiet Urologie

18.04.2024 | Infertilität | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway

Abstract

Objectives

Methods

Results and limitations

Conclusions

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objectives

Methods

Results and limitations

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative

Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011

HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)

Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie